Announcement • Jul 18
Avalo Therapeutics, Inc. has filed a Follow-on Equity Offering. Avalo Therapeutics, Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 128,189
Transaction Features: At the Market Offering Announcement • Jun 23
Avalo Therapeutics, Inc. Announces Appointment of Ron Philip to Board of Directors Avalo Therapeutics, Inc. announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits. Mr. Philip currently serves as Executive Chair of CREATE Medicines. Previously, he served as Chief Executive Officer of Orbital Therapeutics, where he led the company through its $1.5 billion acquisition by Bristol Myers Squibb. Prior to Orbital, Mr. Philip held a series of senior leadership positions at Spark Therapeutics, ultimately serving as Chief Executive Officer. Earlier, he served as Chief Operating Officer and Chief Commercial Officer, leading the commercial launch of LUXTURNA®, Spark’s first FDA-approved gene therapy and the first gene therapy approved in the United States for a genetic disease. During his tenure, he also played a key leadership role in Spark’s $4.8 billion acquisition by Roche. Earlier in his career, Mr. Philip held senior strategy, commercial, and operational leadership roles at Pfizer and Wyeth, where he supported several successful medicines, including ENBREL® and XELJANZ®. He currently serves on the boards of Harmony Biosciences and City Therapeutics. Mr. Philip is a graduate of Drexel University. Announcement • Jun 16
Avalo Therapeutics Expands Pipeline with AVTX-010, A Long-Acting Next-Generation Anti-Il-1? Antibody Avalo Therapeutics announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1ß monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders. AVTX-010 is an engineered anti-IL-1ß mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. AVTX-010 also has the potential to strengthen Avalo’s intellectual property position. The Company expects to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027. Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. The company is also advancing AVTX-010, an engineered anti-IL-1ß mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. Abdakibart is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß) with high affinity and neutralizes its activity. IL-1ß is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases. It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-a, and IL-17. Dysregulated IL-1ß signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1ß inhibition has proven effective in multiple immune-mediated inflammatory diseases. 
